Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Target

PSMA

37 abstracts

Abstract
LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).
Org: Sir Peter MacCallum Department of Oncology, St. Vincent's Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Radiation Oncology, St. Vincent's Medical School,
Abstract
Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.
Org: Memorial Sloan Kettering Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, Institut Gustave Roussy, University Hospital Essen,
Abstract
Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore).
Org: Memorial Sloan Kettering Cancer Center, Carolina Urologic Research Center and GenesisCare US, British Columbia Cancer Agency (BCCA), Veterans Prostate Cancer Awareness, Novartis Pharmaceuticals Corporation,
Abstract
Updated results on the bispecific PSMAxCD3 antibody CC-1 for treatment of prostate cancer.
Org: Clinical Collaboration Unit Translational Immunology, Cluster of Excellence iFIT (EXC2180), Bicony Therapeutics Gmbh, NCT Trial Center and Department of Internal Medicine V and Internal Medicine VI, Charité Comprehensive Cancer Center and Department of Hematology,
Abstract
Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
Org: Centre for Integrative Biology, Department of Cellular, Computational and Integrative Biology,
Abstract
Association of genomic alterations with clinical outcomes following lutetium-177-PSMA vipivotide tetraxetan in men with metastatic castrate-resistant prostate cancer.
Org: Solove Research Institute,
Abstract
A randomized phase 2 trial in progress of flexible and extended dosing of 177Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT).
Org: Department of Nuclear Medicine, School of Medicine, and Klinikum Rechts der Isar, Technical University of Munich, Department of Medicine Statistics Core (DOMStat), Department of Medicine's Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine,
Abstract
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.
Org: GenesisCare, Fort Myers, FL, Telix Pharmaceuticals (Innovations),
Abstract
Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).
Org: Department of Theranostics and Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence, Perth, Western Australia, Australia, ANZUP Cancer Clinical Trials Group,
Abstract
A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.
Org: Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, Coherent Biopharma, Suzhou, China,
Abstract
Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Org: Thomas Jefferson University Hospital, Philadelphia, PA, Florida Cancer Specialists and Research Institute, Sarasota, FL, Amgen, Thousand Oaks, CA, Amgen Europe B.V., Breda, Netherlands,
Abstract
Enrichment of somatic mosaic states involving DNA damage response and repair genes in patients treated with 177Lutetium.
Org: Mayo Clinic Arizona, Phoenix, AZ, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic, Rochester, MN, Division of Medical Oncology, Mayo Clinic, Rochester, MN, Department of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic Comprehensive Cancer Center, Phoenix, AZ,
Abstract
Real world data of 177 Lutetium-PSMA-617 for metastatic castration resistant prostate cancer (mCRPC): Analysis of patients treated from 2 large reference centers.
Org: Oncologia D'OR/Instituto D'OR de Ensino e Pesquisa, Instituto D`Or de Ensino e Pesquisa IDOR,
Abstract
Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) use by US urologists and oncologists.
Org: IQVIA, Inc., Carolina Urologic Research Center/GenesisCare,
Abstract
Real-world treatment patterns with lutetium-177-PSMA-617 (177-Lu-PSMA) in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of California, Irvine, Irvine, CA, Department of Hematology/Oncology, University of California Irvine Medical Center, Hoag Family Cancer Institute and University of Southern California,
Abstract
Baseline PSMA PET/CT as a predictive biomarker for toxicity and patient-reported outcomes in mCRPC patients undergoing 177Lu-PSMA radioligand therapy.
Org: UCLA Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, AIQ Solutions, Madison, WI,
Abstract
Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.
Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Division of Hematology & Medical Oncology, NewYork-Presbyterian Hospital, Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College University,
Abstract
Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.
Org: Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Advanced Accelerator Applications, a Novartis company,
Abstract
177Lu-PSMA radioligand therapy for recurrent/metastatic (R/M) salivary gland cancer (SGC) patients: A phase II pilot study.
Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Radboudumc,
Abstract
PSMA expression and response to 177Lu-PSMA-617 (LuPSMA) in men with vs. without DNA damage repair (DDR) mutations.
Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: The 3TMPO study.
Org: Laval University, CHU de Quebec-Universite Laval, Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, Centre Hospitalier de l’Université de Montréal (CHUM/CRCHUM), University of Sherbrooke,
Abstract
Clinical development of the bispecific PSMAxCD3 antibody CC-1.
Org: University Hospital Tübingen, German Cancer Consortium (DKTK), Partner Site Munich, Department of Internal Medicine, Clinical Collaboration Unit Translational Immunology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center (DKFZ),
Abstract
PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer.
Org: Global Drug Development, Novartis Pharmaceuticals AG, Basel, Switzerland,
Abstract
A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).
Org: Genitourinary Malignancies Branch, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute,
Abstract
Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial.
Org: Epic Sciences, Inc., Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Molecular Imaging and Therapeutic Nuclear Medicine,
Abstract
Do bone scans over-stage disease compared to PSMA PET? An international multicenter retrospective study with blinded independent readers.
Org: Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, University of California, San Francisco, San Francisco, CA, Department of radiology and biomedical imaging, University of California, San Francisco, San Francisco, CA, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany, Department of Nuclear Medicine, University of California, Los Angeles, CA,
Abstract
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.
Org: UCLA Ahmanson Translational Theranostics Division, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, UCLA Nuclear Medicine, Department of Radiology and Biomedical Imaging, University of California Irvine,
Abstract
ProSperA: Phase I study to evaluate safety, tolerability and preliminary efficacy of a bispecific PSMAxCD3 antibody in men with biochemical recurrence of prostate cancer.
Org: University Hospital Tübingen, German Cancer Consortium (DKTK), Partner Site Munich, University Hospital Essen, University of Tübingen, Interfaculty Institute for Cell Biology,
Abstract
Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.
Org: BC Cancer-Vancouver Centre, Vancouver Prostate Centre, Tulane Cancer Center, Gustave Roussy Institute, Memorial Sloan Kettering Cancer Center,
Abstract
Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study.
Org: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, UCLA Department of Medicine, Division of Nuclear Medicine,
Abstract
Real-world data for predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer.
Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Intercept Pharmaceuticals,
Abstract
Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression free survival in patients with prostate cancer.
Org: Stanford University School of Medicine, Progenics Pharmaceuticals, Progenics Pharmaceuticals Inc,
Abstract
Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer.
Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Medicine, Section of Hematology & Oncology, University of Chicago Medical Center, Dana-Farber Cancer Institute, Department of Internal Medicine, Seoul National University Bundang Hospital,
Abstract
Castration-resistant prostate cancer (CRPC) on PSMA-PET: Imaging features, disease distribution, and a comparison to castration-sensitive prostate cancer (CSPC).
Org: Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Hospital of the University of Pennsylvania, Abramson Cancer Center and Perelman School of Medicine,
Abstract
Platinum-based chemotherapy in patients with castration-resistant prostate cancer and hepatic metastases.
Org: Martini-Clinic, Prostate Cancer Center Hamburg and Department of Oncology, University Hospital Hamburg Eppendorf, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Rechts der Isar Medical Center,
Abstract
Lu-PSMA-617 in combination with third-line therapy for castration-resistant prostate cancer: A systemic review and meta-analysis.
Org: North Shore University Hospital, Lincoln Medical Center, Albert Einstein College of Medicine, Jacobi Medical Center/North Central Bronx, Dow Medical College, Karachi, Pakistan,
Abstract
Fully automated prostate cancer identification using multiplex fluorescence immunohistochemistry to assess prognosis markers on a single tissue section.
Org: Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, University Medical Center Hamburg-Eppendorf, University Medical Center Hamburg-Eppendorf (UKE), Martini-Klinik am UKE, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,